Characteristic |
Covid-19 patients (n = 50) |
Influenza patients (n = 45) |
---|---|---|
Age, ya | 48 (42–56) | 58 (48–64) |
Male sex | 36 (72) | 28 (62) |
Symptom-onset-to-ICU-admission interval, daysa | 11 (7–14) | 7 (6–10) |
Admission SAPS IIa,b | 54 (46–65) | 71 (59–79) |
Admission SOFA scorea,c | 12 (10–14) | 15 (10–17) |
Immunocompromisedd | 1 (2) | 4 (9) |
Documented bacterial coinfectiona | 9 (18) | 18 (40) |
Antimicrobial treatment | 50 (100) | 45 (100) |
Days of antimicrobial treatment | 5 (4–6) | 4 (2–7) |
Antiviral agents | ||
Remdesivir | 6 (12) | 0 |
Lopinavir/ritonavir | 9 (18) | 0 |
Hydroxychloroquine | 20 (40) | 0 |
Oseltamivir | 0 | 45 (100) |
Patients with at least one VAP episodea | 43 (86) | 28 (62) |
Number of VAP episodes per patienta | ||
1 | 43 (86) | 28 (62) |
2 | 33 (66) | 17 (38) |
3 | 20 (40) | 8 (18) |
≥ 4 | 11 (22) | 3 (7) |
Days of ECMO support | 21 (10–34) | 18 (8–31) |
Days on mechanical ventilationa,b | 45 (27–62) | 24 (14–45) |
ICU length of stay, daysa | 48 (34–68) | 30 (20–53) |
ICU mortality rate, days | 17 (34) | 18 (40) |